Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 05

1600P - The role of C-reactive protein/albumin ratio in predicting 90-day mortality in patients with febrile neutropenia

Date

10 Sep 2022

Session

Poster session 05

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

Ozan Yazici

Citation

Annals of Oncology (2022) 33 (suppl_7): S713-S742. 10.1016/annonc/annonc1075

Authors

O. Yazici1, O. Sutcuoglu2, N. Rustamova3, A. Uner4, A. Özet2, N. Ozdemir2

Author affiliations

  • 1 Medical Oncology, Gazi University - Faculty of Medicine, 06560 - Ankara/TR
  • 2 Medical Oncology Department, Gazi University - Faculty of Medicine, 06560 - Ankara/TR
  • 3 Medical Oncology, Gazi University - Faculty of Medicine, 34848 - Istanbul/TR
  • 4 Medical Oncology, Gazi University Medical School, 6500 - Ankara/TR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1600P

Background

The MASCC score is widely used to predict the prognosis of febrile neutropenia after chemotherapy in cancer patients. The MASCC score does not use any laboratory data and has low sensitivity. Therefore, the search for markers to predict the prognosis of febrile neutropenia continues. Albumin(alb) and C-Reactive Protein(CRP) are acute phase reactants, besides albumin reflects nutritional status. In this study, we aimed to evaluate the effect of CRP/alb ratio on the prognosis of febrile neutropenia.

Methods

The files of patients admitted with the diagnosis of febrile neutropenia between January 2018 and January 2022 were reviewed retrospectively, MASCC risk score, CRP and albumin levels at admission were collected. All patients who were followed up by the medical oncology department, received at least 1 course of chemotherapy and presented with the diagnosis of febrile neutropenia were included in the study.

Results

A total of one hundred and fifty-six (n=156) episodes of febrile neutropenia were included in the study, and 55 (35%) of these patients died within ninety days. While the 90-day mortality rate was 45% in the group of patients with MASCC <21, this rate was 26% in patients with MASCC >21 (p = 0.007). The median of the CRP/alb ratio was determined as 58 and the patients were divided into two groups according to the median value. The 90-day mortality rate was 24% in the group with a low CRP/alb ratio, and 45% in the group with a high CRP/Alb ratio (p = 0.004). In patients with a MASCC score of >21 and a CRP/alb score of <58 (n=47), the 90-day mortality rate was 21%, compared to 55% in patients with a MASCC <21 and CRP/alb >58 (p= 0.001).

Conclusions

In conclusion, high CRP/Alb ratio worsens the prognosis of febrile neutropenia independently of other factors. The combined evaluation of MASCC risk score and CRP/Alb ratio is beneficial in predicting the prognosis of febrile neutropenia and increases the prognostic power of the MASCC risk score.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.